Literature DB >> 11959904

Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors.

Andrew I Brooks1, Colleen S Stein, Stephanie M Hughes, Jason Heth, Paul M McCray, Sybille L Sauter, Julie C Johnston, Deborah A Cory-Slechta, Howard J Federoff, Beverly L Davidson.   

Abstract

Gene transfer vectors based on lentiviruses can transduce terminally differentiated cells in the brain; however, their ability to reverse established behavioral deficits in animal models of neurodegeneration has not previously been tested. When recombinant feline immunodeficiency virus (FIV)-based vectors expressing beta-glucuronidase were unilaterally injected into the striatum of adult beta-glucuronidase deficient [mucopolysaccharidosis type VII (MPS VII)] mice, an animal model of lysosomal storage disease, there was bihemispheric correction of the characteristic cellular pathology. Moreover, after the injection of FIV-based vectors expressing beta-glucuronidase into brains of beta-glucuronidase-deficient mice with established impairments in spatial learning and memory, there was dramatic recovery of behavioral function. Cognitive improvement resulting from expression of beta-glucuronidase was associated with alteration in expression of genes associated with neuronal plasticity. These data suggest that enzyme replacement to the MPS VII central nervous system goes beyond restoration of beta-glucuronidase activity in the lysosome, and imparts improvements in plasticity and spatial learning.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959904      PMCID: PMC122929          DOI: 10.1073/pnas.082011999

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60.

Authors:  X Cao; T C Südhof
Journal:  Science       Date:  2001-07-06       Impact factor: 47.728

2.  Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII.

Authors:  W A Frisella; L H O'Connor; C A Vogler; M Roberts; S Walkley; B Levy; T M Daly; M S Sands
Journal:  Mol Ther       Date:  2001-03       Impact factor: 11.454

3.  Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis.

Authors:  W S Sly; B A Quinton; W H McAlister; D L Rimoin
Journal:  J Pediatr       Date:  1973-02       Impact factor: 4.406

4.  EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression.

Authors:  R Nagarajan; J Svaren; N Le; T Araki; M Watson; J Milbrandt
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

5.  Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors.

Authors:  J C Johnston; M Gasmi; L E Lim; J H Elder; J K Yee; D J Jolly; K P Campbell; B L Davidson; S L Sauter
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement.

Authors:  S L Sabo; A F Ikin; J D Buxbaum; P Greengard
Journal:  J Cell Biol       Date:  2001-06-25       Impact factor: 10.539

7.  Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission.

Authors:  J K Yamamoto; H Hansen; E W Ho; T Y Morishita; T Okuda; T R Sawa; R M Nakamura; N C Pedersen
Journal:  J Am Vet Med Assoc       Date:  1989-01-15       Impact factor: 1.936

8.  Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity.

Authors:  K Tomonaga; J Norimine; Y S Shin; M Fukasawa; T Miyazawa; A Adachi; T Toyosaki; Y Kawaguchi; C Kai; T Mikami
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

9.  Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation.

Authors:  E H Birkenmeier; J E Barker; C A Vogler; J W Kyle; W S Sly; B Gwynn; B Levy; C Pegors
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

10.  Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency.

Authors:  E H Birkenmeier; M T Davisson; W G Beamer; R E Ganschow; C A Vogler; B Gwynn; K A Lyford; L M Maltais; C J Wawrzyniak
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

View more
  36 in total

Review 1.  Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.

Authors:  William S Sly; Carole Vogler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

3.  Blood to brain to the rescue.

Authors:  Richard L Proia; Yun-Ping Wu
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Inhibition of neuronal phenotype by PTEN in PC12 cells.

Authors:  Sergei Musatov; Jill Roberts; Andrew I Brooks; John Pena; Simone Betchen; Donald W Pfaff; Michael G Kaplitt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-27       Impact factor: 11.205

Review 5.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

Review 6.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

7.  Mitochondrial imaging in dorsal root ganglion neurons following the application of inducible adenoviral vector expressing two fluorescent proteins.

Authors:  Payman Nasr; Patrick G Sullivan; George M Smith
Journal:  J Neurosci Methods       Date:  2008-05-03       Impact factor: 2.390

8.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

Review 9.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

10.  Feline immunodeficiency virus as a gene transfer vector in the rat nucleus tractus solitarii.

Authors:  L H Lin; J E Langasek; L S Talman; O M Taktakishvili; W T Talman
Journal:  Cell Mol Neurobiol       Date:  2009-09-24       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.